TABLE 1.

Therapeutic targeting of Ca²⁺-handling proteins in cardiac hypertrophy, HF and arrhythmia.

Target	Pre-clinical	FDA approved	Clinical trial identifier	Status	Results
S100A1	INXN-4001		NCT03409627	A	N/A
CaM	W-7		Pre-clinical	N/A	N/A
CaMKII	RA306		Pre-clinical	N/A	N/A
	KN-93		Pre-clinical	N/A	N/A
	AAV.GFP.AIP		Pre-clinical	N/A	N/A
AC6	Ad5.hAC6		NCT00787059	C	Safe, tolerable (Hammond et al., 2016)
			NCT03360448	W	N/A
PLN	BMS-986231		NCT03016325	C	Safe, well-tolerated; adverse effects included headaches (Cowart et al., 2019)
			NCT02157506	C	Increased treatment-emergent adverse events in treatment group (>55% in all three regimes vs. 25% in placebo)
			NCT03016325	C	None posted
			NCT03357731	C	None posted
			NCT03730961	C	None posted

For each therapy listed in Figure 3, their status as either pre-clinical or FDA-approved is listed in the table. In addition, any clinical trial information available for the therapies listed in the table is also presented, where NCT denotes the number given to clinical trials on clinicaltrials.gov. Therapies which have yet to enter registered clinical trials are shown as pre-clinical. A brief description on the in human safety and tolerability of each therapy is also shown where available. A, active; C, completed; N/A, not applicable; W, withdrawn.